EP-1140 Dosimetric evaluation of jaw tracking in VMAT of head and neck cancers in True beam STx linear Accelerator
Radiotherapy and Oncology
155 patients (97 male / 58 female) who had histopathologically confirmed NPC treated in our department with definitive-intent RT to a dose of 54 -57 Gy (3 Gy daily fraction) for nasopharyngeal tumour and positive neck lymph nodes. The dose for the prevention irradiation of negative neck lymph nodes was 36 -51 Gy (3 Gy daily fraction). Results: Mean age was 44.9 ± 1.1 years (Range 16-81). Stage I, II, III, IVA and IVB (UICC 2009) were 7, 32, 40, 51 and 25 respectively. 118 patients received
... ients received induction chemotherapy platinum-based. Commonest adverse effects (NCI-CTC 4.0) were: mucositis, dysphagia, and dermatisis. Grade 3 or 4 mucositis, dysphagia, dermatisis occurred in 16 cases (10.3%), 15 cases (9.7%) and 4 cases (2.6%) respectively. Response rate of 154 patients were (1 patient was refused evaluation): complete response 65.6%, Partial response 24.1%, stable disease 7.1% and progressive disease 3.2%. With median follow-up of 18 months, 10 and 15 patients were presented locoregional recurrence and metastasis respectively. The locoregional control (LRC), Metastasis free survival (MFS), disease free survival (DFS) and overall survival (OS) rates at one year were: 95.8% (±1.8%), 89.3% (±2.6%), 85.2 % (±3.1%) and 93.9% (±2.1%), respectively. Conclusions: Preliminary findings using a hypofractionated scheme is a feasible option in the treatment of NPC (an effective regimen with an acceptable safety profile). However, an important number of patients and a longer follow-up are necessary to better appreciate the efficacy and the toxicity outcome (late effect) of this scheme.